Skip to main content
. Author manuscript; available in PMC: 2014 Apr 28.
Published in final edited form as: J Vasc Res. 2012 Aug 30;49(6):510–521. doi: 10.1159/000341216

Figure 3.

Figure 3

RANKL treatment does not enhance SMC calcification. Differentiated BMDMs do not for osteoclasts in response to RANKL. (A) SMCs were treated with CM or HPM in the presence of 100ng/ml of RANKL or vehicle. (B) and (C) TRAP staining. (B) BMDM differentiated for 7 days in M-CSF (20ng/ml) and ten treated for 7 more days with M-CSF (20ng/ml) and RANKL (50ng/ml). (C) RAW264.7 treated for 3 days with RANKL (50 ng/ml) form TRAP positive multinucleated cells.